Literature DB >> 6100430

Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

R D Rolfe, S M Finegold.   

Abstract

The in vitro activity of ceftriaxone was compared with those of other recently introduced beta-lactam antimicrobial agents (cefoperazone, cefotaxime, and moxalactam) and with those of cefoxitin, clindamycin, and metronidazole against 227 strains of anaerobic bacteria. The data obtained in this investigation suggest that ceftriaxone, like a majority of the new beta-lactam antimicrobial agents, may be of limited value in the treatment of serious infections involving anaerobic bacteria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6100430      PMCID: PMC183738          DOI: 10.1128/AAC.22.2.338

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

2.  Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.

Authors:  J H Jorgensen; S A Crawford; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

3.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

4.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.

Authors:  M V Borobio; J Aznar; R Jimenez; F Garcia; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

6.  Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 7.  Gram-negative anaerobic bacilli: their role in infection and patterns of susceptibility to antimicrobial agents. I. Little-known Bacteroides species.

Authors:  B D Kirby; W L George; V L Sutter; D M Citron; S M Finegold
Journal:  Rev Infect Dis       Date:  1980 Nov-Dec

8.  Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538.

Authors:  E J Goldstein; V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  In vitro evaluation of Ro 13-9904.

Authors:  A M Hinkle; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

View more
  17 in total

1.  Influence of Single-Dose Antibiotic Prophylaxis for Early-Onset Pneumonia in High-Risk Intubated Patients.

Authors:  Timothy D Lewis; Kelly A Dehne; Kathryn Morbitzer; Denise H Rhoney; Casey Olm-Shipman; J Dedrick Jordan
Journal:  Neurocrit Care       Date:  2018-06       Impact factor: 3.210

2.  In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.

Authors:  J Wüst; U Hardegger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

3.  Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.

Authors:  W E Owens; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

4.  The influence of third-generation cephalosporins on the aerobic intestinal flora.

Authors:  J P Guggenbichler; J Kofler; F Allerberger
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

7.  In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics.

Authors:  A W Chow; N Cheng; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

8.  Isolation of Clostridium pseudotetanicum from a patient with gas gangrene.

Authors:  N Katoh; K Watanabe; Y Miki; T Muro; K Ueno
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

9.  Factors affecting antimicrobial susceptibility of Fusobacterium species.

Authors:  M D Rowland; V E Del Bene; J W Lewis
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.